Close
New insights into MND: 5 more genetic variants found

New insights into MND: 5 more genetic variants found

Reading Time: 5 minutes A recent study has assessed the extent to which genetics plays a role in the development of MND, in both familial and non-familial (sporadic) forms of the disease. This research has arisen as a result of an international collaboration of several research institutes, many of whom have been supported by the MND Association. The world-class…

Examining the effects of the compound NU-9 in MND mice

Examining the effects of the compound NU-9 in MND mice

Reading Time: 4 minutes A research paper published recently has investigated the effect of a compound called ‘NU-9’ in mice models of MND. Before we go on, it is important to define ‘compound’ in this context. A compound is something that has pharmacological or biological activity that is likely to be therapeutically useful. It serves as a starting point…

Flexible molecules and droplets: researching and targeting RNA-protein complexes in MND

Flexible molecules and droplets: researching and targeting RNA-protein complexes in MND

Reading Time: 6 minutes My name is Tatyana Shelkovnikova, I am an MND Association Lady Edith Wolfson Senior Non-Clinical fellow. I lead my own group at the Medicines Discovery Institute, Cardiff University. I chose to move my fellowship to a drug discovery unit with a strong neuroscience portfolio of projects to be able to stay at the frontier of…

Virtual Symposium: Lessons from COVID-19 Part 3 – Impact on research

Virtual Symposium: Lessons from COVID-19 Part 3 – Impact on research

Reading Time: 3 minutes This is the last in a series of three blog articles from Session 7 – Perspectives: Lessons from COVID-19 in which we heard from different speakers about how the COVID-19 pandemic has impacted their own experiences of clinical trials, research, and support within the MND community. A further blog, written by Bruce Virgo who is…

Virtual Symposium: Lessons from COVID-19 Part 2 – Impact on palliative care

Virtual Symposium: Lessons from COVID-19 Part 2 – Impact on palliative care

Reading Time: 4 minutes This is the second in a series of three blog articles from Session 7 – Perspectives: Lessons from COVID-19 in which we heard from different speakers about how the COVID-19 pandemic has impacted their own experiences of clinical trials, research, and support within the MND community. A further blog, written by Bruce Virgo who is…

Virtual Symposium: Lessons from COVID-19 Part 1 – Impact on clinical trials

Virtual Symposium: Lessons from COVID-19 Part 1 – Impact on clinical trials

Reading Time: 3 minutes This is the first in a series of three blog articles from Session 7 – Perspectives: Lessons from COVID-19 in which we heard from different speakers about how the COVID-19 pandemic has impacted their own experiences of clinical trials, research, and support within the MND community. A further blog, written by Bruce Virgo who is…

Should routine genetic testing be considered for all cases of MND?

Should routine genetic testing be considered for all cases of MND?

Reading Time: 9 minutes A paper arising from research carried out at the University of Sheffield as part of the AMBRoSIA biobank, and in collaboration with the international Project MinE gene-hunting consortium, was recently published in the Journal of Neurology, Neurosurgery and Psychiatry. Researchers propose that a test for the most common MND genes could be offered to all…

Virtual Symposium: Update on AMX0035 CENTAUR and open-label extension trials

Virtual Symposium: Update on AMX0035 CENTAUR and open-label extension trials

Reading Time: 5 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials. Presented by Dr Sabrina Paganoni, from the Sean M. Healey & AMG…